On December 1, 2023, our financial advisor contacted the Companys financial
advisor, who informed us that the Company and the Board do not have an interest in engaging with us without a standstill.
By letter dated
December 12, 2023, we informed the Company we assumed that the failure to timely provide the form of questionnaire and form of written representation letter, each of which was requested in the 2023 Nomination Notice, in contravention of the
Companys Bylaws, is a waiver of the related conditions in the Bylaws. We further noted in this letter that the Company had to date failed to respond to our request in the 2023 Nomination Notice to promptly inform us of any contention that the
2023 Nomination Notice was incomplete or deficient, which, as set forth in the 2023 Nomination Notice, we assumed was an agreement that the 2023 Nomination Notice complied in all respects with the requirements of the Bylaws.
On December 13, 2023, the Company provided the form questionnaire and agreement, stating that they were inadvertently not sent, requested
the questionnaires and agreements be returned by December 29, 2023, and that the Company was still in the process of reviewing the 2023 Nomination Notice sent four weeks prior to such date.
On December 22, 2023, the questionnaires and agreements were provided to the Company on behalf of each of the F9 Nominees, as a courtesy
in light of the Companys failure to timely provide these documents in contravention of its Bylaws, and without waiver of any rights or remedies. We also informed the Company on this date that as previously communicated on a number of
occasions, we remain willing to sign a confidentiality agreement for a potential transaction but not with any provisions that adversely affect our rights with respect to the nominations or any potential transaction with the Company.
During the week of December 18, 2023, there was communication between our advisors and the Companys advisors regarding the terms of
the confidentiality agreement.
On December 26, 2023, our legal counsel, Dentons US LLP (Dentons), informed the
Companys legal counsel, Skadden, Arps, Slate, Meagher & Flom LLP (Skadden), that F9 desired to pursue discussions regarding a negotiated transaction and would sign a confidentiality agreement with a standstill expiring no
later than February 28, 2024.
On December 27, 2023, the Companys financial advisor informed our financial advisor that
the Company was well along in its strategic review process and if we wished to participate in this process, we would be required to provide the Company with an updated proposal that is significantly higher than our last proposal and with
a due diligence request list.
By letter dated January 8, 2024 from Skadden, Arps, Slate, Meagher & Flom LLP, counsel to the
Company (Skadden), to Dentons US LLP, our counsel (Dentons), confirming that the Company was in receipt of, and was reviewing, the 2023 Nomination Notice sent approximately seven weeks earlier and requesting additional
information regarding the F9 Nominees. Also in this letter, we were informed that upon receipt of the requested information, the Company will determine if the F9 Nominees are eligible under applicable law to serve on the Board. The information
request in the January 8 letter was provided to Skadden by Dentons on January10, 2024.
On January 18, 2024, F9 Investments and
Cabinets To Go sent a letter to the chief executive officer and chairperson of the Board withdrawing the offer set forth in the letter of November 14, 2023 to acquire all of the outstanding shares of Common Stock for $3.00 per share in light of
the Companys demand that as a prerequisite to engaging with us, we enter into agreements that may hinder our ability to take actions designed to maximize the value of their investment in the Company. The closing sale price of the Common
Stock on January 18, 2024 was $3.03 per share.
On March 1, 2023, the Company once again reported the
continued erosion of its business in its fourth quarter and year-end financial results, including a full year decrease in net sales of 18.5% and a $3.59 loss per diluted share for the year.7 The closing sale price of the Common Stock on March 1, 2024 was $2.14 per share.
11